Youn Christopher G, Kim Joo Yeon, Yang Vivian B, Bae Gordon H
Department of Dermatology, Stanford University School of Dermatology, 450 Broadway, Pavilion C, 2nd Floor, Redwood City, CA, 94063, United States, 1 650-721-7190.
School of Medicine, University of California, San Francisco School of Medicine, San Francisco, CA, United States.
JMIR Dermatol. 2024 Dec 13;7:e64300. doi: 10.2196/64300.
This observational cost analysis was conducted to assess the efficacy of the Mark Cuban Cost Plus Drug Company (CostPlus) relative to GoodRx and found that CostPlus has significant potential to improve the financial burden of prescription medications within dermatology.
这项观察性成本分析旨在评估马克·库班成本加成制药公司(CostPlus)相对于GoodRx的疗效,发现CostPlus在减轻皮肤科处方药的经济负担方面具有巨大潜力。